Angeliki M. Stamatouli

发表

Implications of the EMPA-REG Trial for Clinical Care and Research

S. Inzucchi, Angeliki M. Stamatouli, 2016, Current Diabetes Reports.

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

Mark S. Anderson, J. Bluestone, S. Gettinger, 2018, Diabetes.

Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor–induced diabetes

Mark S. Anderson, Daniel B. Burkhardt, Smita Krishnaswamy, 2022, JCI insight.

Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors.

James E. Clune, H. Kluger, K. Herold, 2020, Clinical oncology, case reports.

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma

M. Dozmorov, A. Faber, L. Cowart, 2022, Cell stress.

Hypothyroidism: Cardiovascular Endpoints of Thyroid Hormone Replacement

Sahzene Yavuz, Angeliki M. Stamatouli, Pablo Bedoya, 2020, Frontiers in Endocrinology.

Bullous disorders associated with anti–PD‐1 and anti–PD‐L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy

J. Berk-Krauss, M. Sznol, M. Tomayko, 2018, Journal of the American Academy of Dermatology.

Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes

Douglas B. Johnson, K. Herold, J. Moslehi, 2018, Diabetes Care.

Type 2 diabetes mellitus and cardiovascular disease: focus on the effect of antihyperglycemic treatments on cardiovascular outcomes

S. Mayer, I. Jovin, Sumon Roy, 2020, Expert review of cardiovascular therapy.

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma

S. Radhakrishnan, Richard I. J. Kurupi, A. Banito, 2024, bioRxiv.